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Treatment Response and Long Term Follow-up Results of 
Nonspecific Interstitial Pneumonia
The purpose of this study was to investigate the long-term clinical course of non-specific 
interstitial pneumonia (NSIP) and to determine which factors are associated with a response 
to steroid therapy and relapse. Thirty-five patients with pathologically proven NSIP were 
included. Clinical, radiological, and laboratory data were reviewed retrospectively. The 
male-to-female ratio was 7:28 (median age, 52 yr). Thirty (86%) patients responded to 
steroid therapy, and the median follow-up was 55.2 months (range, 15.9-102.0 months). 
Five patients (14%) showed sustained disease progression and three died despite treatment. 
In the five with sustained disease progression, NSIP was associated with various systemic 
conditions, and the seropositivity of fluorescent antinuclear antibody was significantly 
associated with a poor response to steroids (P = 0.028). The rate of relapse was 25%, but 
all relapsed patients improved after re-treatment. The initial dose of steroids was 
significantly low in the relapse group (P = 0.020). In conclusion, progression is associated 
with various systemic conditions in patients who show progression. A low dose of initial 
steroids is significantly associated with relapse.
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ORIGINAL ARTICLE
Respiratory Diseases
INTRODUCTION
Non-specific interstitial pneumonia (NSIP) has been proposed 
as a histological subtype of idiopathic interstitial pneumonia 
and is characterised by varying degrees of alveolar wall inflam-
mation and fibrosis in a pattern that suggests temporal homo-
geneity (1). NSIP is associated with various medical conditions 
such as human immunodeficiency virus infection, hypersensi-
tivity pneumonitis, and several collagen vascular diseases (CVDs) 
including polymyositis-dermatomyositis, rheumatoid arthritis, 
Sjögren’s syndrome, and systemic sclerosis. The diagnosis of id-
iopathic NSIP is made when no specific cause can be detected 
(1-7).
 The overall prognosis and response to steroid therapy is gen-
erally favourable in patients with NSIP (1, 8-12). However, not 
all patients respond well to treatment. In some patients, relapse 
can occur when steroids are tapered or stopped. In others, ste-
roids do not modify disease activity, leading to disease progres-
sion and death. Travis et al. (9) suggested that separating the 
cellular from the fibrotic patterns of NSIP is important because 
survival might differ between these two groups. Patients with 
cellular pattern NSIP have 5- and 10-yr survival rates similar to 
those with desquamative interstitial pneumonia, whereas those 
with fibrotic pattern NSIP have a worse 5-yr survival rate, which 
was similar to those with usual interstitial pneumonia (9). Park 
et al. (13) also reported that patients with fibrotic NSIP are fre-
quently hospitalised with a recurrence rate of 36%. However, 
there are relatively few data on the clinical course and outcomes 
other than mortality. It is also unclear which factors affect the 
responsiveness to steroids and relapse.
 The purpose of this study was to investigate the clinical course 
of NSIP after treatment and to determine which factors are as-
sociated with the responsiveness to steroids and relapse.
 
MATERIALS AND METHODS
Study subjects
We reviewed the medical records of patients admitted to a ter-
tiary referral hospital (Seoul National University Hospital) from 
March 1995 to July 2007. We found 41 patients who were diag-
nosed clinically with NSIP at discharge who had undergone a 
surgical lung biopsy for a histological examination. The biopsy 
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slides were reviewed by three pathologists according to the Amer-
ican Thoracic Society/European Respiratory Society consensus 
classification of interstitial pneumonia (14); and 37 patients with 
pathologically confirmed NSIP were selected. We excluded two 
patients lost to follow-up, so 35 patients were included. 
Variables and definitions
A retrospective study was performed to identify factors associ-
ated with the responsiveness to steroids and relapse. Clinical, 
radiological, and laboratory data were reviewed, including age, 
gender, smoking history, symptoms on admission, comorbidi-
ties, initial oxygen tension in arterial blood (PaO2), results of 
pulmonary function tests, and steroid doses.
 The response to steroid was assessed from the clinical records 
of the patients and included improvement in symptoms, radio-
graphic findings, and pulmonary function tests (PFTs) after ini-
tial corticosteroid therapy. The timing for assessing the response 
was 1 yr after the initiation of treatment. Improvement was de-
fined as > 10% increase in forced vital capacity (FVC) and dif-
fusing capacity of the lung for carbon monoxide (DLCO). Progres-
sion was defined as > 10% decline in FVC and DLCO from base-
line and/or death. When the PFT data could not be obtained 
because of worsening of respiratory symptoms accompanied 
by continued worsening of findings on chest radiography (e.g. 
acute exacerbation), the case was also defined as disease pro-
gression. Patients who did not demonstrate improvement or 
progression were considered stable. Finally, we classified the 
patients who showed improvement or remained stable after 
the initial steroid therapy as steroid responders, and those who 
showed progression as steroid non-responders.
 Relapse was defined as an aggravation of symptoms and lung 
function (and/or radiological abnormalities) after complete dis-
continuation of treatment and treatment with prednisolone and/ 
or cytotoxic agent was restarted.
Analysis
Continuous variables were analysed in the univariate analysis 
using non-parametric tests (Mann-Whitney U- or Kruskal-Wal-
lis tests), and categorical variables were compared using Pear-
son’s chi-squared or Fisher’s exact test, as appropriate. Survival 
was evaluated using the Kaplan-Meier method. A survival anal-
ysis was performed on the total sample, including patients with 
cellular or fibrotic NSIP, because the number of patients was 
small, only three deaths occurred, and the histological subtypes 
could not be distinguished in many patients. SPSS version 17.0 
(Chicago, IL, USA) was used for all analyses. A P value < 0.05 
was considered significant.
Ethics statement
The study was approved by the institutional review board of 
Seoul National University Hospital (Approval No. H-1008-095-
328). The board waived informed consent from the subject pa-
tients. This study was conducted in accordance with the Decla-
ration of Helsinki.
 
RESULTS
Twenty-eight women and seven men (median age, 52 yr) were 
included in the analysis. The demographic and clinical charac-
teristics of the enrolled patients are described in Table 1. Most 
patients presented with subacute onset of dyspnea or cough. 
Ground-glass opacity was the most frequent abnormality (88.6%), 
Table 1. Baseline characteristics
Parameters    Findings
Total (number) 35 (100%)
Age (yr) 52 (35-68)
Female sex 28 (80%)
Smoking status (n = 26)
   Never smoker
   Ex-smoker
   Current smoker
 
17 (65.4%)
7 (26.9%)
2 (7.7%)
Symptoms
   Dyspnea
   Cough
   Sputum
   Weight loss
   Fever
 
29 (82.9%)
27 (77.1%)
20 (57.1%)
6 (17.1%)
5 (14.3%)
Duration of symptoms, months (n = 33) 2 (0.3-120)
Radiological feature 
   Ground-glass opacity
   Consolidation
   Traction bronchiectasis
   Reticulation
   Honeycombing
 
31 (88.6%)
14 (40.0%)
12 (34.3%)
8 (22.9%)
6 (17.1%)
Histological pattern 
   Cellular
   Fibrotic
   Indeterminate
 
17 (48.6%)
10 (28.6%)
8 (22.9%)
Comorbidities
   Collagen vascular disease*
   Diabetes mellitus
   Tuberculosis
   Malignancy
   Hypertension
 
9 (25.7%)
7 (20.0%)
7 (20.0%)
5 (14.3%)
4 (11.4%)
Initial BAL finding % (n = 18)
   Total cells × 105 (counts/µL)
   Macrophages (%)
   Neutrophils (%)
   Lymphocytes (%)
   Eosinophils (%)
   T4/T8 ratio (n = 16)
  
3.99 (0.67-27.4)
27 (0-90)
6.5 (0-35)
34.5 (6-76)
0.5 (0-44)
0.38 (0.10-2.52)
Initial pulmonary function tests
   FVC, % pred (n = 34)
   DLCO, % pred (n = 32)
  
63.5 (32-103)
46.5 (26-95)
Initial PaO2, mmHg (n = 27) 73.1 (45.3-112.0)
Follow-up duration, months (range) (n = 32)† 55.2 (15.9-102.0)
 Values in parentheses represent the range or percentage. *Sjogren syndrome (n = 4, 
11.4%), mixed connective tissue disease (n = 2, 5.7%), polymyositis (n = 1, 2.9%), 
diffuse scleroderma (n = 1, 2.9%), rheumatoid arthritis (n = 1, 2.9%), dermatomyo-
sitis (n = 1, 2.9%); †Follow-up duration of survivors. BAL, bronchoalveolar lavage; 
FVC, forced vital capacity; pred, predicted; DLCO, diffusing capacity of the lung for 
carbon monoxide; PaO2, oxygen tension in arterial blood.
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Fig. 1. Clinical courses of the patients with nonspecific in-
terstitial pneumonia (NSIP).
No relapse 
n = 18 (75%)
Relapse 
n = 6 (25%)
Alive 
n = 18 (100%)
Alive 
n = 6 (100%)
Steroid responder 
n = 30 (86%)
Improvement 
n = 24 (80%)
Biopsy-proven NSIP 
n = 35
Stable 
n = 6 (20%)
Alive 
n = 6 (100%)
Alive 
n = 2 (40%)
Dead 
n = 3 (60%)
Progression 
n = 5 (100%)
Steroid non-responder 
n = 5 (14%)
Table 2. Comparison between steroid responders and non-responders
Variables Steroid responders (n = 30) Steroid non-responders  (n = 5) P  value
Age (yr)  53.5 (35-68)    51 (49-58) 0.962
Female sex      24 (80.0%)       4 (80.0%) > 0.999
Duration of symptoms, months (n = 33)          2.0 (0.3-120.0)     12.0 (2.0-36.0) 0.221
Never-smoker (n = 26)      16 (66.7%)       1 (50.0%) > 0.999
Histologic pattern (n = 27)
   Cellular
   Fibrotic
 
     15 (65.2%)
       8 (34.8%)
 
      2 (50.0%)
      2 (50.0%)
 
0.613
Collagen vascular disease        6 (20.0%)       3 (60.0%) 0.095
Presence of systemic condition*      15 (50.0%)      5 (100%) 0.057
Radiological feature 
   Ground-glass opacity
   Consolidation
   Traction bronchiectasis 
   Reticulation
   Honeycombing
 
     27 (90.0%)
     11 (36.7%)
       9 (30.0%)
       7 (23.3%)
       5 (16.7%)
 
      4 (80.0%)
      3 (60.0%)
      3 (60.0%)
      1 (20.0%)
      1 (20.0%)
 
0.477
0.369
0.313
> 0.999
> 0.999
Initial BAL finding % (n = 18)
   Total cells × 105 (counts/µL) 
   Macrophages (%)
   Neutrophils (%)
   Lymphocytes (%)
   Eosinophils (%)
   T4/T8 ratio (n = 16)
 
     4.15 (0.67-25) 
   18 (0-90)
        7 (0-33.0)
   40 (6-76)
     1 (0-44)
        0.46 (0.10-2.52)
 
      3.30 (2.61-27.4) 
   46 (30-67)
   6 (2-35)
   27 (23-40)
 0 (0-2)
      0.31 (0.21-0.55)
 
0.594
0.373
0.905
0.635
0.485
0.638
Initial laboratory findings, median (range)
   WBC (counts/µL)
   Cholesterol, mg/dL (n = 34)
   Albumin, g/dL (n = 34)
   CRP, mg/dL (n = 31)
   ESR, mm/hr (n = 20)
   RF positive, n (%) (n = 24)
   FANA positive, n (%) (n = 24)
            8,275 (3,630-13,480)
       175 (116-312)
      3.9 (2.5-4.6)
        0.47 (0.01-9.91)
   27 (1-78)
     8 (36.4)
     5 (23.8)
          8,200 (5,480-37,700)
     186 (147-191)
    3.4 (2.9-4.0)
      0.51 (0.01-7.98)
55.5 (47-72)
   1 (50.0)
     3 (100.0)
0.556
0.957
0.179
0.86
0.053
> 0.999
0.028
Initial pulmonary function tests
   FVC, % pred (n = 34)
   DLCO, % pred (n = 32)
 
       64 (41-103)
  46.5 (26-95)
 
   62 (32-90)
53.5 (37-77)
 
0.511
0.732
Initial PaO2, mmHg (n = 27)            75 (45.3-99.1)         66.4 (57.0-112.0) 0.339
Values in parentheses represent the range or percentage. *The systemic conditions included collagen vascular disease, malignancy, diabetes mellitus, pulmonary tuberculosis, 
hepatitis B, and sustained exposure to drugs or chemicals (Table 3, E1, E2). BAL, bronchoalveolar lavage; WBC, white blood cells; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; RF, rheumatoid factor; FANA, fluorescent antinuclear antibody; FVC, forced vital capacity; pred, predicted; DLCO, diffusing capacity of the lung for carbon 
monoxide; PaO2, oxygen tension in arterial blood.
followed by consolidation (40.0%) on the initial chest comput-
ed tomography (CT) scans. A histological analysis showed the 
cellular pattern in 17 patients (48.6%) and the fibrotic pattern in 
10 patients (28.6%); the histological NSIP subtype was indeter-
minate in eight patients (22.9%). The median follow-up dura-
tion for survivors was 55.2 months (range, 15.9-102.0 months).
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 The follow-up results of the enrolled patients are summarised 
in Fig. 1. All 35 patients received corticosteroid therapy alone as 
the initial treatment, and cytotoxic agents were added in seven 
patients (four patients cyclophosphamide; three patients aza-
thioprine) who showed rapid disease progression or steroid 
dependency. The median dose of initial prednisolone was 0.54 
mg/kg/day. A higher dose of initial steroids (> 1.5 mg/kg/day) 
was used in only two patients, 9.5 mg/kg/day in one patient who 
showed rapid disease progression, and 1.8 mg/kg/day in another 
who showed arterial hypoxemia on room air (PaO2, 54.3 mmHg). 
The range of initial prednisolone doses used in patients except 
these two was 0.4-1.1 mg/kg/day. The prednisolone dose was 
slowly tapered after 4-6 weeks based on the clinical and PFT 
evaluation of early response. Thirty (86%) patients responded 
to steroid therapy, and five (14%) were considered non-respond-
ers. Three of the 5 non-responders died of disease progression 
with combined pneumonia, although all had received addition-
al cyclophosphamide pulse therapy. The patients died 1.6, 1.7, 
and 5.2 months after beginning treatment. In contrast, steroid 
responders were all alive at the end of the follow-up period. Six 
(20%) steroid responders were stable but were considered ste-
roid dependent because the disease worsened when steroids 
were reduced. Therefore, steroid treatment was maintained in 
these six patients for the entire follow-up period, and azathio-
prine was added in two patients. The maintenance dose of pred-
nisolone was 5 mg in five patients and 15 mg in one patient. The 
1- and 5-yr survival rates in all patients were 97.1% and 93.9%, 
respectively.
 Table 2 shows a comparison of various parameters between 
steroid responders and non-responders. Histological subtype 
was not related to steroid response. Smoking history, period 
from the onset of symptoms to treatment, initial chest CT find-
ings, initial PFT results, and initial bronchoalveolar lavage find-
ings did not differ between the groups. However, seropositivity 
for the fluorescent antinuclear antibody (FANA) was significant-
ly associated with a poor response to steroids. Higher erythro-
cyte sedimentation rate (ESR) tended to be related to disease 
progression. Table 3 shows the clinical characteristics of steroid 
non-responders. Most of the patients with poor treatment out-
comes had underlying systemic conditions associated with NSIP, 
such as CVD or exposure to drugs.
 Twenty-four (80%) of the 30 steroid responders showed clini-
cal improvement after initial treatment, and 18 (75%) remained 
relapse free during the median follow-up of 41.5 months (range, 
5.1-76.4 months) after discontinuing the steroids. Relapses oc-
curred in six (25%) of 24 patients within a median of 8.2 months 
(range, 3.0-16.4 months) after withdrawal of steroids. Patients 
who relapsed were all retreated with a median steroid dose of 
30 mg (range, 25-30 mg), and azathioprine was added in one 
patient. The median duration of retreatment was 4.3 months 
(range, 3.5-10.7 months) in four patients, and steroid treatment 
was maintained in another two patients. Patients with and with-
out relapse were compared to search for predictive factors (Tables 
4 and 5). The initial dose of prednisolone was significantly low-
er in the relapse group. Additionally, the duration of initial treat-
ment tended to be shorter in the relapse group (4.7 vs 7.7 months), 
Table 3. Characteristics of the progression group
Age (yr)/ 
   sex
Background Histology
Period from  
onset of symp-
toms to treat-
ment (months)
Additional therapy
Follow-up  
duration, months
Prognosis
50/F Diffuse scleroderma Fibrotic 36.0 Cyclophosphamide pulse 65.2 Alive
49/F MCTD with RA overlap syndrome I 12.0 Rituximab 39.1 Alive
51/F Dermatomyositis, Sjögren’s syndrome Fibrotic   2.0 Cyclophosphamide pulse 26 Dead
52/F ALL with imatinib treatment Cellular   2.0 Cyclophosphamide pulse 61.3 Dead
58/M HBV carrier, painter Cellular 12.0 Cyclophosphamide pulse 1.6 Dead
MCTD, mixed connective tissue disease; RA, rheumatoid arthritis; I, indeterminate; ALL, acute lymphoblastic leukaemia; HBV, hepatitis B virus.
Table 4. Comparison of clinical and radiological features between the no relapse and 
relapse groups
Variables
No relapse 
(n = 18)
Relapse  
(n = 6)
P  value
Age (yr) 55.5 (35-68) 45 (39-59) 0.109
Female sex 14 (77.8%) 5 (83.3%) > 0.999
Duration of symptoms, 
   months (n = 22)
2.0 (0.3-120.0) 4.0 (2.0-12.0) 0.372
Never smoked (n = 22) 10 (62.5%) 5 (83.3%) 0.616
Histological pattern (n = 18)
   Cellular
   Fibrotic
 
6 (50.0%)
6 (50.0%)
 
5 (83.3%)
1 (16.7%)
 
0.316
Collagen vascular disease 4 (22.2%) 1 (16.7%) > 0.999
Presence of systemic condition* 8 (44.4%) 3 (50.0%) > 0.999
Radiological feature 
   Ground-glass opacity
   Consolidation
   Traction bronchiectasis 
   Reticulation
   Honeycombing
 
17 (94.4%)
9 (50.0%)
4 (22.2%)
4 (22.2%)
4 (22.2%)
 
5 (83.3%)
1 (16.7%)
2 (33.3%)
2 (33.3%)
0 (0%)
 
0.446
0.341
0.618
0.618
0.539
Initial treatment
   Initial dose of prednisolone (mg) 
   Initial dose of prednisolone (mg/kg)
   Total duration (months)
 
38 (25-100)
0.6 (0.5-1.8)
7.7 (3.3-24.9)
 
30 (25-35)
0.5 (0.5-0.5)
4.7 (2.5-12.2)
0.028
0.020
0.182
Follow-up duration, months (range) 53.4 (15.9-94.7) 37.9 (18.9-78.2) 0.257
Values in parentheses represent the range or percentage. *The systemic conditions 
included collagen vascular disease, malignancy, diabetes mellitus, pulmonary tuber-
culosis, hepatitis B, and sustained exposure to drugs or chemicals (Table E2).
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but no statistical significance was observed. Smoking history, 
histological pattern, presence of CVD, initial chest CT, and PFT 
and laboratory findings did not differ significantly between the 
groups. The detailed lists of underlying systemic conditions in 
steroid responders are summarized in Tables E1 and E2.
 Both FVC and DLCO improved gradually in both the cellular 
and fibrotic NSIP groups. DLCO tended to be higher in patients 
with cellular NSIP than in those with fibrotic NSIP throughout 
the follow-up period, although the difference was not signifi-
cant. A comparison of the PFT results between patients with 
and without CVD showed that FVC and DLCO tended to be low-
er in patients with CVD than in those without CVD but without 
statistical significance. Patients with CVD tended to have fewer 
changes in PFT results, however this difference was not signifi-
cant (data not shown).
DISCUSSION
The NSIP population showed clinical similarities to previous 
study populations with a predominance of never-smoking, mid-
dle-aged females (15, 16). In our study, the overall prognosis of 
patients with NSIP was generally favourable with an initial re-
sponse rate to steroid therapy of 86% and a 5-yr survival rate of 
93.9%. The overall 5-yr survival rate varied in previous studies 
(1, 3, 8, 17-19); and this variation could be explained by the het-
erogeneity of the populations studied in terms of histological 
subtypes and the underlying conditions associated with NSIP. 
The survival rates in our study were higher than those reported 
previously in patients with fibrotic NSIP but were lower than 
those in patients with cellular NSIP (3, 9, 13, 18).
 The presence of an underlying systemic condition might be 
relevant to a poor prognosis for patients with NSIP. Notably, all 
five patients in the progression group had chronic diseases or 
associated conditions such as CVD and sustained exposure to 
drugs or chemicals. Among the three patients who died, one 
had dermatomyositis and Sjögren’s syndrome and another had 
a history of sustained exposure to paint fumes for > 40 yr. An-
other patient had acute lymphoblastic leukaemia and had been 
treated with imatinib for about 15 months before NSIP was di-
agnosed. She died of progressive NSIP, although complete re-
mission of leukaemia had been achieved. FANA seropositivity 
was also significantly associated with progression, and the ini-
tial ESR level tended to be higher in the progression group. An-
ti-nuclear antibodies are found in patients not only with auto-
immune diseases but also those with various non-rheumato-
logical conditions associated with tissue damage such as infec-
tions, cancer, and hormonal or blood diseases. Recent studies 
have shown that even idiopathic NSIP might be associated with 
an autoimmune background that later reveals itself as an organ-
specific or a systemic autoimmune disease (20, 21). Thus, we 
presumed that the presence of ANA might be an early manifes-
tation of this systemic background and that simultaneous sys-
temic manifestations might be related to a poor prognosis. This 
possibility parallels our results showing the patients with NSIP 
and various systemic conditions had worse prognoses. Unfor-
tunately, we found no statistically significant relationship be-
tween the systemic conditions and poor prognosis for NSIP, 
probably because of the small sample size and the heterogene-
ity of associated conditions. The pathophysiological responses 
to injury grade might differ between patients with various con-
ditions associated with NSIP. Felício et al. (22) detected signifi-
cantly greater collagen and elastic fibre proliferation in the lungs 
of patients with CVD and NSIP compared with those with idio-
pathic NSIP. The increased elastosis may have been caused by 
major repair and remodelling processes following septal inflam-
mation and consequent fiber fragmentation. These processes 
might also be responsible for the loss of the normal alveolar wall 
architecture, which contributes to alveoli collapse, thereby im-
pairing the mechanisms of inflammatory resolution (22). Re-
cently, a case series of progressive NSIP revealed a change in 
histology to a more fibrous pattern through sequential biopsies, 
and half of the patients had CVD (23). Progression of fibropro-
liferation is associated with poor outcomes in response to ste-
roid treatment (24).
 Among the steroid responders in our study, up to 40% of pa-
tients suffered relapse or steroid dependency. Park et al. (13) 
reported that relapse occurred in 36% of patients with fibrotic 
NSIP who improved or were stable after initial treatment, and 
Table 5. Laboratory findings and pulmonary function tests in the no relapse and re-
lapse groups
Variables
No relapse 
(n = 18)
Relapse  
(n = 6)
P  value
Initial BAL finding % (n = 11)
   Total cells × 105, counts/µL
   Macrophages
   Neutrophils
   Lymphocytes
   Eosinophils
   T4/T8 ratio
4.50 (0.67-25)
24 (0-90)
7 (0-21)
46 (6-76)
0 (0-33)
0.27 (0.10-2.52)
3.99 (1.68-4.32)
 14 (6-44)
 6 (3-16)
 39 (25-73)
6.5 (1-44)
0.50 (0.23-0.75)
  
0.705
0.570
0.850
0.636
0.065
0.705
Initial laboratory findings, 
   median (range)
   WBC (counts/µL)
   Cholesterol (mg/dL)
   Albumin (g/dL)
   CRP, mg/dL (n = 23)
   ESR, mm/hr (n = 15)
   RF positive, No. (%) (n = 19)
   FANA positive, No. (%) (n = 18)
8,945  
(3,630-13,480)
 189 (122-312)
 3.8 (2.5-4.6)
0.47 (0.01-9.91)
24 (1-55)
 5 (33.3)
 3 (20.0)
7,200  
(4,440-10,300)
161 (116-197)
4.1 (3.7-4.2)
0.26 (0.14-1.72)
 74 (22-78)
1 (25.0)
2 (66.7)
  
0.317
0.125
0.131
0.575
0.083
> 0.999
0.172
Initial PaO2, mmHg (n = 19) 72.8 (45.3-99.1) 86.8 (80.2-94.0) 0.057
Initial pulmonary function tests
   FVC, % pred (n = 23)
   DLCO, % pred (n = 22)
 
65 (41-103)
55 (26-95)
 
64 (53-79)
42.5 (33-92)
 
> 0.999
0.740
Values in parentheses represent the range or percentage. BAL, bronchoalveolar la-
vage; WBC, white blood cells; CRP, C-reactive protein; ESR, erythrocyte sedimentation 
rate; RF, rheumatoid factor; FANA, fluorescent antinuclear antibody; FVC, forced vital 
capacity; pred, predicted; DLCO, diffusing capacity of the lung for carbon monoxide.
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the disease-related mortality was 30% in this subgroup. In con-
trast, all of the relapsed patients in our study showed improve-
ment after re-treatment with steroids, and none of the patients 
in this subgroup died. We also found that a lower dose of initial 
steroid was associated with a relapse of NSIP, a finding that con-
trasts with that of Park et al. (13). However, the initial doses of 
steroid in the study by Park et al. (13) were higher than the dos-
es used in both the relapse and no relapse groups in our study. 
The study by Park et al. (13) included only patients with fibrotic 
NSIP, whereas we included both cellular and fibrotic subtypes 
in the analysis of relapse. The optimal dose and duration of glu-
cocorticoid therapy is still unclear because most studies of pa-
tients with NSIP used a variety of regimens in a small number 
of patients (8, 13, 19, 22, 24, 25).
 This study had some limitations. First, it was a retrospective 
study with a small sample size, so a multivariate analysis could 
not be performed. Second, the pathological subtypes could not 
be confirmed in all patients, although we attempted to identify 
the pathological patterns in all patients. Third, a possibility of 
selection bias existed between the biopsy group and the non-
biopsy group in patients with CVD and NSIP. Surgical biopsy 
was performed in most patients with atypical radiological fea-
tures other than usual interstitial pneumonia. However, we be-
lieve that it is difficult to make a correct clinical diagnosis of the 
various types of CVD based solely on CT findings (26). Finally, 
our study population included a heterogeneous group with var-
ious underlying conditions associated with NSIP.
 In conclusion, we investigated the treatment course of NSIP 
and identified several prognostic factors for treatment response 
and relapse. In patients who show sustained disease progres-
sion despite treatment, the progression is associated with vari-
ous systemic conditions such as CVD, malignancy, or exposure 
to drugs or chemicals. A lower dose of initial steroids is signifi-
cantly associated with relapse. 
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